"Pharmaceutical Speed Reader" Yan Jian and another senior executive leave "limited resistance order" to upgrade.

July 23, 2020 / Medical Information List: Another executive leaves, the State Council: the key tasks for deepening the reform of the medical and health system in the second half of the year; the re-escalation of the "resistance restraining order", the new Pfizer/BioNTech vaccine received a $1.95 billion order from the U.S. government, encoded announced the completion of a $135 million Round D financing... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief State Council: Deepening the reform of the medical and health system in the second half of the key tasks The General Office of the State Council issued the "Key tasks for deepening the reform of the medical and health system in the second half of 2020", which mentioned strengthening the construction of the public health system, in-depth implementation of the Healthy China Initiative, deepening the comprehensive reform of public hospitals, and improving the drug supply security system.
(General Office of the State Council) "Restriction order" re-upgrading The National Health and Care Commission issued new regulations on all doctors the National Health and Care Commission issued "on the continued good management of the clinical application of antimicrobial drugs notice", mentioned that medical institutions to implement the main responsibility of the clinical application management of antimicrobial drugs, and put forward specific requirements, some of these provisions and front-line doctors are closely related, such as physicians without medical institutions training and assessment, not to grant antimicrobial prescription rights.
(National Health and Health Commission) National Four Departments issued a message: check the names of all medical institutions Prohibit "by brand name" recently, the State Health and Health Commission, the General Office of the Ministry of Civil Affairs, the General Office of Market Supervision, the Office of the State Administration of Traditional Chinese Medicine four departments jointly issued "on the further standardization of the management of medical institutions name notice", requiring that from now on, all medical institutions name inspection and clean-up.
the name of medical institutions is a medical institution signed a legal matter, the brand is the facade, the name is left to the patient's first impression, but if there is speculation, deliberate imitation and other acts, is a violation, will be punished and banned accordingly.
(Primary Physicians Commune) Part 2 Executive Director's Departure, Jian Jian announced the appointment of Michael McDonnell to replace Jeffrey Capello as Executive Vice President and Chief Financial Officer, effective August 15, 2020.
, capello is the second executive to leave the company in the last year, following the departure of Michael Ehlers, the former head of research and development.
(Sina) Pfizer/BioNTech's new vaccine received a $1.95 billion u.S. government order, Pfizer/BioNTech and the U.S. government signed a larger vaccine agreement under the agreement, pfizer/BioNTech jointly developed mRNA new crown candidate vaccine BNT162 after the U.S. FDA authorized or approved, the U.S. government will receive the first 100 million doses of the vaccine, and pay it up to $1.95 billion.
(Sina Pharmaceutical News) Encoded announced the completion of the amount of 135 million U.S. dollars in D-round financing recently, the National Health and Health Commission, the Ministry of Civil Affairs Office, the General Administration of Market Supervision 22, committed to the development of precision gene therapy Encoded Therapeutics announced the completion of the amount of 135 million U.S. dollars in D-round financing.
investors include GV, Matrix Capital Management and ARCH Venture Partners.
the funds raised for this round will be used to promote its precision gene therapy for the treatment of Dravet syndrome.
(Immediate Medicine) Howson Pharmaceuticals authorized EQRx Inc. Ametini's interests outside China, Henson Pharmaceuticals (Shanghai) Health Technologies and Howson Pharmaceuticals and EQRx Co., Inc. entered into a strategic partnership and license agreement to grant EQRx exclusive license to develop, produce and commercialize the former third generation of EGFR-TKI Amitini outside China, covering the treatment areas of cancer, cancer-related and inflammatory diseases.
down payment, registration and development milestone paymentforth of the transaction is approximately $100 million.
(Hanson Pharmaceutical Announcement) Part 3 Pharmaceutical Information Therapy nAMD Roche Rejure monoanti-glass implant 98% of patients achieved a six-month interval, Roche announced the detailed results of the Phase III ARCHWAY trial.
studies compared the new in-eye administration system ranibizumab PDS (Rebead Monoanti-Glass Implant) at a fixed interval of 6 months with a monthly injection of raybead monotorthin in the glass.
rchway study reached the primary endpoint: 98.4 percent of PDS patients were able to rehydrate every six months without additional treatment, and the visual results were consistent with those receiving a monthly reinceration.
(Sina Pharmaceutical News) AXA PharmaceuticalS MDM2-p53 Inhibitor China 1b Phase 1b Study Completed the first patient-to-drug Administration Yasheng Pharmaceuticals 22, announced that the company is working on the original class 1 new drug 2-p53 inhibitor APG-115 as a single drug and joint treatment of adult recurrence or difficult treatment of acute myeloid leukemia, recurrence or progress of high-risk/extremely high-risk myeloidal hyperplasia syndrome 1b clinical study, has completed the first clinical study of patients in China.
as the first MDM2-p53 inhibitor to enter clinical phase in China for the treatment of solid tumors, this is the first clinical study of APG-115 to engage in blood tumor indications.
(Pharmaceutical Mission) Cell Therapy FCR001 completed the first live kidney transplant patient administration in Phase 3 clinical lysa, Talaris Therapeutics announced that it has completed the first live kidney transplant patient administration in a phase 3 clinical trial called FREEDOM-1 in Cell Therapy FCR001, which is designed to evaluate the safety and effectiveness of FCR001 single-dose administration.
(immediate drug news) repolar medicine in the research of new drugs in China to apply for breakthrough treatment drugs 22, re-extreme medicine announced to the State Drug Administration to submit an application, identified in the research drug MAX-40279 for the treatment of FLT3 wild type of acute myeloid leukemia breakthrough treatment drugs.
FLT3 is a key target for the treatment of acute myeloid leukemia.
(Pharmaceutical Rubik's Cube) Junshi BioDAC-002 Injections approved by clinical trials Junshi Bio 22 issued a notice that the company's product SS108 (DAC-002) recently obtained the approval of the State Drug Administration issued the "Drug Clinical Trial Approval Notice", agreed to carry out clinical trials for the treatment of advanced solid malignancies.
(Junshi Biological Announcement) BoYu Innovation freeze-dried human rabies vaccine with rabies vaccine approved drug clinical trial notice Bo-Yu innovation announcement that the company's holding Sun Company Zhongke Bio and Chengdu Boottke signed a "project cooperation contract" in January 2020, jointly declared freeze-dried human rabies vaccine (no serum Vero cells) products.
the product recently received approval from the State Drug Administration to issue the "Drug Clinical Trial Approval Notice."
(Boao Innovation Announcement) FDA approved innovative narcolepsy therapy listed Hengrui Pharmaceuticals announced that the company and subsidiary Suzhou Shengdiasheng Jazz Pharmaceuticals announced that the U.S. FDA approved xwavy oral fluids for the market on July 21, 2020 for the treatment of patients with narcolepsy 7 years and older or excessive daytime narration.
Xywav is a new type of hydroxybutyrate drug, and its unique cation composition results in sodium content 92% lower than the current standard treatment for these patients, reducing the risk of excessive sodium ion intake. scientists
have found the cause of chloroquine's poor COVID-19 treatment, a new study by a European research team published in an accelerated preview.
researchers have found that while chloroquine prevents the new coronavirus from invading cells in commonly used renal cell lines, it is not effective in preventing the new coronavirus from invading cells in lung cell lines.
researchers say the findings underscore the importance of testing the efficacy of potential therapies with cell lines that simulate lung epithelial cells.
(The Drug Mingcon) Re-discussed the role of the important pathological protein sydns of Alzheimer's disease published online today in the journal Cell, pointing out that perhaps we shouldn't ignore amyloid deposits and simply assume that it's just a product of disease.
, on the contrary, it may still promote the onset of Alzheimer's disease.
(Academic Latitude)